AT-41MULTI-CENTER CLINICAL TRIAL OF INTRAVENOUS ADMINISTRATION OF BEVACIZUMAB FOR THE TREATMENT OF RADIATION NECROSIS IN THE BRAIN TO OBTAIN NDA APPLICATION FOR ON LABEL USE IN JAPAN

Abstract

Recent radiotherapeutic modalities including particle radiotherapy, IMRT, and SRS are able to irradiate tumor tissue with high absorbed doses. These radiation therapies are promising to provide a longer survival in patients with CNS malignant tumors, compared to conventional X-ray radiotherapy. Simultaneously radiation necrosis (RN) has been a serious problem in such patients. However, there is no effective treatment for progressive RN so far. VEGF has been reported to play an important role in the progression of RN. Some clinical reports including ours demonstrate good results of bevacizumab treatment for RN. However, so far, no country gives a permission to use bevacizumab for symptomatic radiation necrosisin the brain as on label use. We initiated a nation-wide multicenter clinical trial in Japan, with the correct diagnosis of RN by amino-acid PET, to obtain a new drug approval (NDA) applications from Japanese FDA, based on public knowledge. Primary endpoint was the improvement of cerebral edema in periodic MRI. Secondary endpoint were safety, reduction of steroids, improvement of KPS and recurrence rate of RN within a year. The back ground of the patients are as follows; primary brain tumors such as GBM, metastatic brain tumors and head and neck cancers are 28 cases (68.3%), 12 cases (29.3%) and 1 case (2.4%), respectively. Applied radiation modalities are as follows; external beam radio-therapy 17 cases, SES 29 cases, hypo-fractionated IMRT 4 cases, proton beam particle radiation 3 cases and boron neutron capture therapy 1 case. Totally 41 cases of patients' enrollment finished. Last patient, last visit was in April 2014. The results are now opening and hopefully we can present them in SNO meeting.